{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"60.0","value":"22.2"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"41.0","value":"0.0"},{"groupId":"OG003","lowerLimit":"15.3","upperLimit":"50.8","value":"31.0"},{"groupId":"OG004","lowerLimit":"1.9","upperLimit":"45.4","value":"15.4"},{"groupId":"OG005","lowerLimit":"5.2","upperLimit":"40.3","value":"18.2"},{"groupId":"OG006","lowerLimit":"8.4","upperLimit":"58.1","value":"28.6"},{"groupId":"OG007","lowerLimit":"5.3","upperLimit":"85.3","value":"40.0"},{"groupId":"OG008","lowerLimit":"18.4","upperLimit":"90.1","value":"57.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"7"}],"units":"Participants"}],"description":"The percentage of participants achieving a complete response (CR), CR with incomplete neutrophil recovery (CRi), or a CR with incomplete platelet recovery (CRp), based on the 2003 revised IWG criteria for AML and 2006 modified IWG criteria for MDS per investigator review. CR: - ANC \\> 1.0 x10⁹/L - Platelet count \\> 100 x10⁹/L - Bone marrow (BM) blasts \\< 5% - Absence of blasts with Auer rods - Independence of red cell transfusions CRi: - All CR criteria except for residual neutropenia (ANC \\< 1.0 x 10⁹/L CRp: - All CR criteria except for residual thrombocytopenia (platelet counts \\< 100 x 10⁹/L)","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received enasidenib 50 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Phase 1 Dose Escalation: Enasidenib 50 mg"},{"description":"Participants who received a total daily dose of enasidenib 60 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG001","title":"Phase 1 Dose Escalation: Enasidenib 60 mg"},{"description":"Participants who received a total daily dose of enasidenib 75 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG002","title":"Phase 1 Dose Escalation: Enasidenib 75 mg"},{"description":"Participants who received a total daily dose of enasidenib 100 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG003","title":"Phase 1 Dose Escalation: Enasidenib 100 mg"},{"description":"Participants who received a total daily dose of enasidenib 150 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG004","title":"Phase 1 Dose Escalation: Enasidenib 150 mg"},{"description":"Participants who received a total daily dose of enasidenib 200 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG005","title":"Phase 1 Dose Escalation: Enasidenib 200 mg"},{"description":"Participants who received a total daily dose of enasidenib 300 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG006","title":"Phase 1 Dose Escalation: Enasidenib 300 mg"},{"description":"Participants who received a total daily dose of enasidenib 450 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG007","title":"Phase 1 Dose Escalation: Enasidenib 450 mg"},{"description":"Participants who received a total daily dose of enasidenib 650 mg on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG008","title":"Phase 1 Dose Escalation: Enasidenib 650 mg"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study treatment in Phase 1 Dose Escalation. Participants were grouped according to assigned total daily dose.","reportingStatus":"POSTED","timeFrame":"Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in the Phase 1 Dose Escalation was 5.0 months (range 0.4 to 34.2 months).","title":"Phase 1 Dose Escalation: Rate of Complete Response and Complete Response With Incomplete Hematological Recovery (CR/CRi/CRp) by Total Daily Dose","type":"SECONDARY","unitOfMeasure":"percentage of participants"}